Home  »  Industry   »  Why should you keep an eye on Allogene Therapeutic...

Why should you keep an eye on Allogene Therapeutics Inc. (ALLO)?

Allogene Therapeutics Inc. (NASDAQ: ALLO) is 26.23% higher on its value in year-to-date trading and has touched a low of $5.41 and a high of $17.49 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALLO stock was last observed hovering at around $6.86 in the last trading session, with the day’s gains setting it 1.08% off its average median price target of $17.00 for the next 12 months. It is also 85.56% off the consensus price target high of $55.00 offered by 19 analysts, but current levels are -32.33% lower than the price target low of $6.00 for the same period.

Currently trading at $7.94, the stock is 27.09% and 0.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.86 million and changing 15.74% at the moment leaves the stock -23.05% off its SMA200. ALLO registered -30.11% loss for a year compared to 6-month loss of -41.70%.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…

Sponsored

The stock witnessed a 27.04% gain in the last 1 month and extending the period to 3 months gives it a -21.07%, and is 14.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.60% over the week and 8.19% over the month.

Allogene Therapeutics Inc. (ALLO) has around 356 employees, a market worth around $1.11B and $0.20M in sales. Distance from 52-week low is 46.90% and -54.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.90%).

Allogene Therapeutics Inc. (ALLO) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Allogene Therapeutics Inc. (ALLO) is a “Overweight”. 19 analysts offering their recommendations for the stock have an average rating of 2.00, where 3 rate it as a Hold and 1 think it is a “Overweight”. 14 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Allogene Therapeutics Inc. is expected to release its quarterly report on 05/10/2023.The EPS is expected to grow by 9.00% this year.

Allogene Therapeutics Inc. (ALLO) Top Institutional Holders

The shares outstanding are 143.66M, and float is at 82.54M with Short Float at 40.50%.

Allogene Therapeutics Inc. (ALLO) Insider Activity

A total of 9 insider transactions have happened at Allogene Therapeutics Inc. (ALLO) in the last six months, with sales accounting for 8 and purchases happening 1 times. The most recent transaction is an insider sale by Bhavnagri Veer,the company’sGeneral Counsel. SEC filings show that Bhavnagri Veer sold 3,000 shares of the company’s common stock on Jan 17 at a price of $7.04 per share for a total of $21120.0. Following the sale, the insider now owns 0.58 million shares.

Allogene Therapeutics Inc. disclosed in a document filed with the SEC on Dec 15 that Bhavnagri Veer (General Counsel) sold a total of 5,602 shares of the company’s common stock. The trade occurred on Dec 15 and was made at $7.53 per share for $42186.0. Following the transaction, the insider now directly holds 0.58 million shares of the ALLO stock.

Still, SEC filings show that on Aug 12, WITTE OWEN N. (Director) disposed off 5,000 shares at an average price of $17.25 for $86250.0. The insider now directly holds 218,271 shares of Allogene Therapeutics Inc. (ALLO).

Allogene Therapeutics Inc. (ALLO): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 2.09% up over the past 12 months and AbbVie Inc. (ABBV) that is 11.90% higher over the same period.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts